A region between NHR1 and NHR2 affects latency of leukemogenesis. These results provide valuable insight into further analysis of the molecular mechanism of t(8;21) in leukemogenesis.
Introduction
The AML1-ETO (AE) protein from a common chromosomal translocation t(8;21) contains five known functional domains (Fig. 1A) , the Drosophila runt homology domain (RHD) from AML1 and four Drosophila Nervy homology regions (NHRs) from ETO. The Runt domain is responsible for binding to DNA, interacting with its heterodimerization partner CBFβ, and binding to other transcription regulators.
1;2 NHR1 shares sequence similarity with TAF110. NHR2
is critical for ETO oligomerization; NHR3 contains a predicted coiled-coil structure; NHR4 is a myeloid-Nervy-DEAF1 (MYND) homology domain with zinc chelating motifs.
To understand the molecular mechanism of AE in leukemogenesis, several mouse models have been established. Studies using these models revealed that AE expression was not sufficient to induce leukemia. [3] [4] [5] [6] [7] However, with additional mutation(s), AE is necessary for causing AML. 8;9 Recently, we identified C-terminal truncated AE proteins (AEtr and AE9a) as potent inducers of leukemia development in mice. 10;11 Interestingly, the naturally occurring spliced isoform AE9a was detected in t(8;21) patients. 11 In this report, we investigated the importance of different known AE domains in leukemogenesis using the AE9a mouse leukemia model. 
Results and Discussion
To investigate the important domains of AE in leukemogenesis, we used a series of point mutation and internal deletion mutants of C-terminal truncated AE proteins to perform hematopoietic cell retroviral transduction and transplantation assays (Fig. 1A) . The expression of these fusion proteins was confirmed by western blotting (Fig. 1B) . Based on previous reports, the L148D mutation should disrupt AE binding to DNA and CBFβ, 13 , it is still possible that the binding of certain factor(s) to the RHD contributes to the oncogenic function of this fusion protein.
The median survival time of AE9a mice and AE9a-delNHR1 mice was 10.1 and 10.5 weeks, respectively (Fig. 1D ). In contrast, a significant delay in leukemia development was observed in AE9a-del(350-428) mice. 
